Logo Image
Opinion|Videos|December 23, 2024

Examining Axatilimab in the AGAVE-201 Trial For cGVHD

Sergio A. Giralt, MD, discusses how the mechanism of action of axatilimab, recently approved by the FDA for chronic graft-vs-host disease (cGVHD), involves targeting CSF1R to disrupt macrophage differentiation and reduce inflammation, and how the AGAVE-201 trial demonstrated strong efficacy and safety, which will influence clinical decision-making and potentially change the GVHD treatment landscape by offering a novel therapeutic option.

Episodes in this series

Video content above is prompted by the following:

  • What did this abstract elucidate about the mechanism of action of axatilimab, which was approved by the FDA this year as a treatment for chronic graft-vs-host disease (cGVHD)?
  • How will this abstract affect your clinical decision-making?
  • The AGAVE-201 trial led to the approval of axatilimab for cGVHD. Discuss the methods and study design of this trial.
  • What were the key efficacy and safety data seen in the AGAVE-201 trial with axatilimab?
  • How do these results influence your clinical practice?
  • How do you see the GVHD treatment landscape changing with the introduction of axatilimab?

Related Content